RxDoctor Payments Data

Idalia Fernandez-Sloves

Nurse Practitioner · New York, NYNPI 1336180629

Payments from drug & device makers

$8,324in general payments, 2019–2025

Across 77 payments — averaging $108.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$7K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$486
  • Ipsen Biopharmaceuticals, Inc$418
  • Intercept Pharmaceuticals, Inc.$251
  • Madrigal Pharmaceuticals$185
  • Orphalan Inc$163
  • plus $208 from 3 others

What the payments were for

  • Consulting fees$2,64032%
  • Travel & lodging$2,10125%
  • Food & beverage$3,58343%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,324 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$7,932
Medicare patients
40
Services billed
123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcalivaObeticholic Acid28$367,883
XifaxanRifaximin53$172,522
VemlidyTenofovir Alafenamide41$69,654
Everolimus30$24,397
Ursodiol136$20,527
Tacrolimus138$15,742
Mycophenolate Mofetil43$8,809
Entecavir54$7,259
Posaconazole12$6,813
LokelmaSodium Zirconium Cyclosilicate12$5,280
Mycophenolic AcidMycophenolate Sodium36$4,179
Lactulose27$1,299
Azathioprine29$1,151
Tenofovir Disoproxil Fumarate12$584
Pantoprazole Sodium52$304

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Intercept Pharmaceuticals, Inc.Ocaliva$251$367,88328 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$486$172,52253 claims
GileadVemlidy$6,612$69,65441 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →